Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.

Author: BossiAlberto, BrigantiAlberto, De MeerleerGert, DecaesteckerKarel, GiannariniGianluca, KarnesR Jeffrey, OstPiet, RoachMack

Paper Details 
Original Abstract of the Article :
CONTEXT: The introduction of novel imaging modalities has increased the detection of oligometastatic prostate cancer (PCa) recurrence, potentially justifying the use of a metastasis-directed therapy (MDT) with surgery or radiotherapy (RT) rather than a systemic approach. OBJECTIVE: To perform a sys...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.eururo.2014.09.004

データ提供:米国国立医学図書館(NLM)

Metastasis-Directed Therapy: A Targeted Approach for Prostate Cancer Recurrence

In the vast and ever-evolving desert of cancer treatment, researchers are continuously searching for more precise and effective strategies to combat this relentless disease. This study focuses on the potential of metastasis-directed therapy (MDT) for treating oligometastatic prostate cancer (PCa), a condition characterized by a small number of cancer cells spreading to distant sites.

A New Oasis in Prostate Cancer Treatment

The study explores the use of MDT, which targets specific metastatic sites with surgery or radiotherapy (RT), as opposed to systemic treatments. The researchers analyzed data from fifteen case series, involving 450 patients, to assess the effectiveness and safety of MDT for oligometastatic PCa recurrence. They found that MDT, particularly with RT, yielded promising outcomes, with 51% of patients remaining progression-free for 1-3 years after treatment. However, the study acknowledges that further research, especially randomized controlled trials, is needed to validate these findings and establish MDT as a standard of care.

Navigating the Desert of Prostate Cancer

This study sheds light on the potential of MDT as a promising tool for treating oligometastatic PCa. The research underscores the importance of individualized treatment approaches, considering the specific characteristics of the disease and the patient's condition. As we continue to navigate the vast desert of cancer treatment, MDT offers a glimmer of hope, potentially providing a more targeted and effective way to combat this formidable foe.

Dr.Camel's Conclusion

In the desert of cancer treatment, researchers are constantly searching for new oases of hope. This study suggests that MDT may be a promising oasis for treating oligometastatic PCa, offering a more targeted approach to combat the disease. While further research is needed, this research presents a valuable step forward in the fight against prostate cancer.
Date :
  1. Date Completed 2016-01-05
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

25240974

DOI: Digital Object Identifier

10.1016/j.eururo.2014.09.004

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.